Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Genome Biologics provides TrueCardium® human cardiac organoid NAM platform services. It is positioned not as traditional SaaS, but as a CRO-style screening and disease-modeling platform for pharmaceutical, biotech, and translational research teams. Its core value lies in using vascularized, innervated, multicellular 3D iPSC-derived cardiac organoids to complement the limitations of traditional 2D in vitro experiments and animal models in translational prediction.
The platform covers cardiotoxicity and QT liability screening, disease models such as HFpEF/fibrosis/inflammation/rare cardiovascular diseases, efficacy validation, target validation, patient-specific iPSC organoid response testing, and multi-omics analyses including transcriptomics, proteomics, metabolomics, and spatial transcriptomics. Readouts include viability, LDH, hsTnT, contractility, calcium transients, electrophysiology, Seahorse OCR/ECAR, fibrosis and inflammatory pathways, and more. The website also highlights GENISYST® for modeling complex disease heterogeneity and AI-supported analysis.
Pricing is not publicly disclosed. It uses a project-based/service-package model, and users need to contact the company to obtain a research proposal. Disclosed packages include Cardiac Liability Screen, Regulatory-Grade Cardiotoxicity Package, Disease Model Efficacy Study, and Custom Discovery Partnership. Some studies are typically delivered within 2–6 weeks, but the exact timeline depends on model complexity and experimental design.
Its strengths are the high biological complexity of its models, support for multidimensional readouts and mechanistic interpretation, and the fact that TrueCardium® data has been reviewed in regulatory contexts related to BfArM and the U.S. FDA, making it suitable as a supplement to nonclinical pharmacology packages. Its weaknesses include the lack of public pricing, payment methods, standard contracts, and IP details. From an enterprise software perspective, it does not disclose APIs, permissions, cloud deployment, system integration, or information security certifications.
It is better suited to cardiovascular drug R&D, pre-IND safety de-risking, precision medicine, and mechanistic research projects, and is not suitable for companies looking for a general-purpose SaaS tool. Access from China is not confirmed in the main content and needs to be tested directly. Cross-border collaboration also requires attention to compliance around samples, data, contracts, and logistics.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on genomebiologics.com official site.
genomebiologics.com is an Germany Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach genomebiologics.com directly.